GlassScriptPhysician profile
Carmen Dunbar
NPI 1144986951
$2,467.56
in general payments reported to CMS, 2019-2025
19 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.44 · 2023: $824 · 2024: $502 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166 · Education: $242 · Travel and Lodging: $20.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.28 |
| Education | $241.99 |
| Travel and Lodging | $20.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $782.70 | 2023-2025 | |
| Axsome Therapeutics, INC. | $423.31 | 2022-2025 | Sunosi, Symbravo |
| Abbvie INC. | $240.25 | 2025 | |
| Inspire Medical Systems, INC. | $145.80 | 2023-2024 | Inspire |
| Livanova USA, INC. | $129.25 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $120.50 | 2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $115.48 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $100.30 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $96.07 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $84.99 | 2024 | |
| Acadia Pharmaceuticals INC | $46.78 | 2025 | Nuplazid |
| Biogen, INC. | $40.38 | 2025 | Skyclarys, Leqembi |
| Genentech USA, INC. | $26.45 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $26.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.03 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.52 | 2025 | Uplizna |
| Novo Nordisk INC | $18.32 | 2022 | |
| Ucb, INC. | $16.39 | 2025 | Fintepla |
| Tonix Medicines, INC. | $15.66 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Dunbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.